Pinkham, Mark B. http://orcid.org/0000-0001-8886-728X
Herschtal, A.
Hong, A. M.
Chua, M. S. -T.
Scolyer, R. A.
Cumming, S.
Pullar, A.
Nobes, J.
Barker, C. A.
Guadagnolo, B. A.
Fogarty, G. B.
Burmeister, B. H.
Foote, M. C.
Funding for this research was provided by:
Cancer Australia (APP1060687)
National Health and Medical Research Council (Investigator Grant (2022/GNT2018514))
The University of Queensland
Article History
Received: 26 March 2024
Accepted: 21 May 2024
First Online: 8 June 2024
Disclosures
: M. B. Pinkham has received fees for professional services from Servier, Roche, Bristol-Myers Squibb, Astra Zenica, and Elekta. A. M. Hong has received fees for professional service from Telix. R. A. Scolyer has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. C. A. Barker leads clinical trials supported by Elekta, Merck, Amgen, EMD Serono, Alpha Tau Medical, and Regeneron for which his institution has received funding. He has served as a paid scientific advisor to Regeneron and as an unpaid scientific advisor to Castle Biosciences. M. C. Foote has received fees for professional services from Elekta and Varian. The remaining authors have no conflicts of interest.